tetano
Editor, Senior Moderator
Ann Lab Med
. 2024 Mar 12.
doi: 10.3343/alm.2023.0395. Online ahead of print. Platelet and Monocyte Microvesicles as Potential Biomarkers of COVID-19 Severity: A Cross-Sectional Analysis
Nastasya Nunki[SUP] 1 2 [/SUP], Yetti Hernaningsih[SUP] 3 [/SUP], Puspa Wardhani[SUP] 3 4 5 [/SUP], Asih Herawati[SUP] 6 [/SUP], Narazah Mohd Yusoff[SUP] 3 7 [/SUP], Emmanuel Jairaj Moses[SUP] 7 8 [/SUP], Bambang Pujo Semedi[SUP] 9 [/SUP]
Affiliations
Background: Coronavirus disease (COVID-19) induces inflammation, coagulopathy following platelet and monocyte activation, and fibrinolysis, resulting in elevated D-dimer levels. Activated platelets and monocytes produce microvesicles (MVs). We analyzed the differences in platelet and monocyte MV counts in mild, moderate, and severe COVID-19, as well as their correlation with D-dimer levels.
Methods: In this cross-sectional study, blood specimens were collected from 90 COVID-19 patients and analyzed for D-dimers using SYSMEX CS-2500. Platelet MVs (PMVs; PMVCD42b[SUP]+[/SUP] and PMVCD41a[SUP]+[/SUP]), monocyte MVs (MMVs; MMVCD14[SUP]+[/SUP]), and phosphatidylserine-binding annexin V (PS, AnnV[SUP]+[/SUP]) were analyzed using a BD FACSCalibur instrument.
Results: PMV and MMV counts were significantly increased in COVID-19 patients. AnnV[SUP]+[/SUP] PMVCD42b[SUP]+[/SUP] and AnnV[SUP]+[/SUP] PMVCD41a[SUP]+[/SUP] cell counts were higher in patients with severe COVID-19 than in those with moderate clinical symptoms. The median (range) of AnnV[SUP]+[/SUP] PMVCD42b[SUP]+[/SUP] (MV/μL) in mild, moderate, and severe COVID-19 was 1,118.3 (328.1-1,910.5), 937.4 (311.4-2,909.5), and 1,298.8 (458.2-9,703.5), respectively (P=0.009). The median (range) for AnnV[SUP]+[/SUP] PMVCD41a[SUP]+[/SUP] (MV/μL) in mild, moderate, and severe disease was 885.5 (346.3-1,682.7), 663.5 (233.8-2,081.5), and 1,146.3 (333.3-10,296.6), respectively (P=0.007). D-dimer levels (ng/mL) weak correlated with AnnV[SUP]+[/SUP] PMVCD41a[SUP]+[/SUP] (P=0.047, r=0.258).
Conclusions: PMV PMVCD42b[SUP]+[/SUP] and PMVCD41a[SUP]+[/SUP] counts were significantly increased in patients with severe clinical symptoms, and PMVCD41a[SUP]+[/SUP] counts correlated with D-dimer levels. Therefore, MV counts can be used as a potential biomarker of COVID-19 severity.
Keywords: Annexin V; CD14; CD41a; CD42b; COVID-19; D-dimer; Microvesicles.
. 2024 Mar 12.
doi: 10.3343/alm.2023.0395. Online ahead of print. Platelet and Monocyte Microvesicles as Potential Biomarkers of COVID-19 Severity: A Cross-Sectional Analysis
Nastasya Nunki[SUP] 1 2 [/SUP], Yetti Hernaningsih[SUP] 3 [/SUP], Puspa Wardhani[SUP] 3 4 5 [/SUP], Asih Herawati[SUP] 6 [/SUP], Narazah Mohd Yusoff[SUP] 3 7 [/SUP], Emmanuel Jairaj Moses[SUP] 7 8 [/SUP], Bambang Pujo Semedi[SUP] 9 [/SUP]
Affiliations
- PMID: 38469637
- DOI: 10.3343/alm.2023.0395
Background: Coronavirus disease (COVID-19) induces inflammation, coagulopathy following platelet and monocyte activation, and fibrinolysis, resulting in elevated D-dimer levels. Activated platelets and monocytes produce microvesicles (MVs). We analyzed the differences in platelet and monocyte MV counts in mild, moderate, and severe COVID-19, as well as their correlation with D-dimer levels.
Methods: In this cross-sectional study, blood specimens were collected from 90 COVID-19 patients and analyzed for D-dimers using SYSMEX CS-2500. Platelet MVs (PMVs; PMVCD42b[SUP]+[/SUP] and PMVCD41a[SUP]+[/SUP]), monocyte MVs (MMVs; MMVCD14[SUP]+[/SUP]), and phosphatidylserine-binding annexin V (PS, AnnV[SUP]+[/SUP]) were analyzed using a BD FACSCalibur instrument.
Results: PMV and MMV counts were significantly increased in COVID-19 patients. AnnV[SUP]+[/SUP] PMVCD42b[SUP]+[/SUP] and AnnV[SUP]+[/SUP] PMVCD41a[SUP]+[/SUP] cell counts were higher in patients with severe COVID-19 than in those with moderate clinical symptoms. The median (range) of AnnV[SUP]+[/SUP] PMVCD42b[SUP]+[/SUP] (MV/μL) in mild, moderate, and severe COVID-19 was 1,118.3 (328.1-1,910.5), 937.4 (311.4-2,909.5), and 1,298.8 (458.2-9,703.5), respectively (P=0.009). The median (range) for AnnV[SUP]+[/SUP] PMVCD41a[SUP]+[/SUP] (MV/μL) in mild, moderate, and severe disease was 885.5 (346.3-1,682.7), 663.5 (233.8-2,081.5), and 1,146.3 (333.3-10,296.6), respectively (P=0.007). D-dimer levels (ng/mL) weak correlated with AnnV[SUP]+[/SUP] PMVCD41a[SUP]+[/SUP] (P=0.047, r=0.258).
Conclusions: PMV PMVCD42b[SUP]+[/SUP] and PMVCD41a[SUP]+[/SUP] counts were significantly increased in patients with severe clinical symptoms, and PMVCD41a[SUP]+[/SUP] counts correlated with D-dimer levels. Therefore, MV counts can be used as a potential biomarker of COVID-19 severity.
Keywords: Annexin V; CD14; CD41a; CD42b; COVID-19; D-dimer; Microvesicles.